Selonsertib

Overview

Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 ( ASK1 ) inhibitor with a pIC 50 of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Obesity | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MAP3K | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-18938
• CAS No.: 1448428-04-3
• Molecular Formula: C24H24FN7O
• Molecular Weight: 445.49
• Purity: 99.05%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.62 mg/mL (5.88 mM); Clear solution
• Availability: In-stock

Source

Original product source